• SPX
  • $5,971.54
  • 0.38 %
  • $22.83
  • DJI
  • $44,232.74
  • 0.83 %
  • $362.38
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,262.08
  • 1.38 %
  • $112.81
  • IXIC
  • $19,019.52
  • 0.25 %
  • $47.10
Autolus Therapeutics plc (AUTL) Stock Price, News & Analysis

Autolus Therapeutics plc (AUTL) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.95

$0.11

(3.87%)

Day's range
$2.76
Day's range
$3.05
50-day range
$2.69
Day's range
$5
  • Country: GB
  • ISIN: US05280R1005
52 wk range
$2.69
Day's range
$7.45
  • CEO: Dr. Christian Martin Itin Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -0.22
  • Piotroski Score 3.00
  • Grade Buy
  • Symbol (AUTL)
  • Company Autolus Therapeutics plc
  • Price $2.95
  • Changes Percentage (3.87%)
  • Change $0.11
  • Day Low $2.76
  • Day High $3.05
  • Year High $7.45

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/11/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $8.00
  • High Stock Price Target $11.00
  • Low Stock Price Target $7.60
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.21
  • Trailing P/E Ratio -3.31
  • Forward P/E Ratio -3.31
  • P/E Growth -3.31
  • Net Income $-208,383,000

Income Statement

Quarterly

Annual

Latest News of AUTL

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Autolus Therapeutics plc Frequently Asked Questions

  • What is the Autolus Therapeutics plc stock price today?

    Today's price of Autolus Therapeutics plc is $2.95 — it has increased by +3.87% in the past 24 hours. Watch Autolus Therapeutics plc stock price performance more closely on the chart.

  • Does Autolus Therapeutics plc release reports?

    Yes, you can track Autolus Therapeutics plc's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Autolus Therapeutics plc stock forecast?

    Watch the Autolus Therapeutics plc chart and read a more detailed Autolus Therapeutics plc stock forecast to see what analysts suggest you do with its shares.

  • What is Autolus Therapeutics plc stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Autolus Therapeutics plc stock ticker.

  • How to buy Autolus Therapeutics plc stocks?

    Like other stocks, AUTL shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Autolus Therapeutics plc's EBITDA?

    Autolus Therapeutics plc measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Autolus Therapeutics plc’s financial statements.

  • What is the Autolus Therapeutics plc's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -122.722614841, which equates to approximately -12,272.26%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Autolus Therapeutics plc stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Autolus Therapeutics plc's financials relevant news, and technical analysis. Autolus Therapeutics plc's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Autolus Therapeutics plc stock currently indicates a “sell” signal. For more insights, review Autolus Therapeutics plc’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.